{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:53:03Z","timestamp":1791496383289,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00708-w","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:35:54Z","timestamp":1746506154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-3748","authenticated-orcid":false,"given":"Volkan","family":"Aslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-8397","authenticated-orcid":false,"given":"Atiye Cenay","family":"Karab\u00f6rk K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-2149","authenticated-orcid":false,"given":"Nigar","family":"Rustamova Cennet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6516-3150","authenticated-orcid":false,"given":"Talha alperen","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-0534","authenticated-orcid":false,"given":"Bediz","family":"kurt inci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-5793","authenticated-orcid":false,"given":"Fatih","family":"g\u00fcrler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-9636","authenticated-orcid":false,"given":"Ahmet","family":"\u00d6zet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-9592","authenticated-orcid":false,"given":"Nuriye","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-1755","authenticated-orcid":false,"given":"Huseyin Koray","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0038-3569","authenticated-orcid":false,"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"6","key":"708_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck, M., Remon, J. & Hellmann, M. D. First-line immunotherapy for non\u2013small-cell lung cancer. J. Clin. Oncol. 40(6), 586\u2013597 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"708_CR2","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non\u2013small-cell lung cancer. N. Engl. J. Med. 372(21), 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"708_CR3","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.2006.09.0274","volume":"25","author":"H Schmidt","year":"2007","unstructured":"Schmidt, H. et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American joint committee on Cancer stage IV melanoma: Results of the EORTC 18951 biochemotherapy trial. J. Clin. Oncol. 25(12), 1562\u20131569 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"708_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4062\/biomolther.2023.132","volume":"31","author":"ES Kim","year":"2023","unstructured":"Kim, E. S., Kim, S. Y. & Moon, A. C-reactive protein signaling pathways in tumor progression. Biomolecules Ther. 31(5), 473 (2023).","journal-title":"Biomolecules Ther."},{"issue":"8","key":"708_CR5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/cancers16081508","volume":"16","author":"M Stares","year":"2024","unstructured":"Stares, M. et al. Prognostic biomarkers of systemic inflammation in Non-Small cell lung cancer: A narrative review of challenges and opportunities. Cancers 16(8), 1508 (2024).","journal-title":"Cancers"},{"issue":"1","key":"708_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5(1), 3\u20138 (2017).","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"708_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","volume":"39","author":"V Bronte","year":"2013","unstructured":"Bronte, V. & Pittet, M. J. The spleen in local and systemic regulation of immunity. Immunity 39(5), 806\u2013818 (2013).","journal-title":"Immunity"},{"issue":"18","key":"708_CR8","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","volume":"76","author":"E Limagne","year":"2016","unstructured":"Limagne, E. et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX\u2013bevacizumab drug treatment regimen. Cancer Res. 76(18), 5241\u20135252 (2016).","journal-title":"Cancer Res."},{"issue":"12","key":"708_CR9","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3390\/cancers13123020","volume":"13","author":"L Galland","year":"2021","unstructured":"Galland, L. et al. Splenic volume as a surrogate marker of immune checkpoint inhibitor efficacy in metastatic Non small cell lung cancer. Cancers 13(12), 3020 (2021).","journal-title":"Cancers"},{"key":"708_CR10","unstructured":"Organization, W. H. & Online News-room fact-sheets detail obesity and overweight. URL: (2020). https:\/\/www.who.int\/newsroom\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"708_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s003300050145","volume":"7","author":"P Prassopoulos","year":"1997","unstructured":"Prassopoulos, P. et al. Determination of normal Splenic volume on computed tomography in relation to age, gender and body habitus. Eur. Radiol. 7, 246\u2013248 (1997).","journal-title":"Eur. Radiol."},{"issue":"6","key":"708_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/cancers12061429","volume":"12","author":"J Niogret","year":"2020","unstructured":"Niogret, J. et al. Baseline Splenic volume as a prognostic biomarker of FOLFIRI efficacy and a surrogate marker of MDSC accumulation in metastatic colorectal carcinoma. Cancers 12(6), 1429 (2020).","journal-title":"Cancers"},{"key":"708_CR13","doi-asserted-by":"crossref","unstructured":"Liu, C. et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J. Immunother. Cancer 9(1). (2021).","DOI":"10.1136\/jitc-2020-001895"},{"issue":"12","key":"708_CR14","doi-asserted-by":"publisher","first-page":"e0144","DOI":"10.1097\/MD.0000000000010144","volume":"97","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine 97(12), e0144 (2018).","journal-title":"Medicine"},{"key":"708_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00262-016-1953-z","volume":"66","author":"KR Jordan","year":"2017","unstructured":"Jordan, K. R. et al. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Cancer Immunol. Immunother. 66, 503\u2013513 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"708_CR16","doi-asserted-by":"publisher","first-page":"e17375","DOI":"10.7554\/eLife.17375","volume":"5","author":"AW Ku","year":"2016","unstructured":"Ku, A. W. et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife 5, e17375 (2016).","journal-title":"Elife"},{"issue":"12","key":"708_CR17","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/eji.202048666","volume":"50","author":"E Tavukcuoglu","year":"2020","unstructured":"Tavukcuoglu, E. et al. Human Splenic polymorphonuclear myeloid-derived suppressor cells (PMN\u2010MDSC) are strategically located immune regulatory cells in cancer. Eur. J. Immunol. 50(12), 2067\u20132074 (2020).","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"708_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 12(1), 729 (2021).","journal-title":"Nat. Commun."},{"key":"708_CR19","doi-asserted-by":"crossref","unstructured":"Balkwill, F. R. & Mantovani, A. Cancer-related Inflammation: Common Themes and Therapeutic Opportunities. In Seminars In cancer Biology (Elsevier, 2012).","DOI":"10.1016\/j.semcancer.2011.12.005"},{"key":"708_CR20","doi-asserted-by":"crossref","unstructured":"Boissier, R. et al. The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review. in Urologic Oncology: Seminars and Original Investigations. Elsevier. (2017).","DOI":"10.1016\/j.urolonc.2017.01.016"},{"issue":"1","key":"708_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cncr.31778","volume":"125","author":"MA Bilen","year":"2019","unstructured":"Bilen, M. A. et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer 125(1), 127\u2013134 (2019).","journal-title":"Cancer"},{"issue":"3","key":"708_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells9030561","volume":"9","author":"AM Law","year":"2020","unstructured":"Law, A. M., Valdes-Mora, F. & Gallego-Ortega, D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells 9(3), 561 (2020).","journal-title":"Cells"},{"key":"708_CR23","doi-asserted-by":"crossref","unstructured":"Alessi, J. V. et al. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J. Immunother. Cancer, 9(11). (2021).","DOI":"10.1136\/jitc-2021-003536"},{"key":"708_CR24","doi-asserted-by":"crossref","unstructured":"Hwang, M. et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J. Immunother. Cancer 10(6). (2022).","DOI":"10.1136\/jitc-2022-004688"},{"key":"708_CR25","doi-asserted-by":"crossref","unstructured":"Anpalakhan, S. et al. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: an INVIDIa-2 study sub-analysis. Iscience 26(11). (2023).","DOI":"10.1016\/j.isci.2023.107970"},{"issue":"7","key":"708_CR26","doi-asserted-by":"publisher","first-page":"e0270950","DOI":"10.1371\/journal.pone.0270950","volume":"17","author":"F Castagnoli","year":"2022","unstructured":"Castagnoli, F. et al. Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. Plos One. 17(7), e0270950 (2022).","journal-title":"Plos One"},{"issue":"11","key":"708_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2217\/imt-2021-0022","volume":"13","author":"L Susok","year":"2021","unstructured":"Susok, L. et al. Volume increase of spleen in melanoma patients undergoing immune checkpoint Blockade. Immunotherapy 13(11), 885\u2013891 (2021).","journal-title":"Immunotherapy"},{"issue":"15","key":"708_CR28","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3390\/cancers14153574","volume":"14","author":"L M\u00fcller","year":"2022","unstructured":"M\u00fcller, L. et al. Baseline Splenic volume outweighs Immuno-Modulated size changes with regard to survival outcome in patients with hepatocellular carcinoma under immunotherapy. Cancers 14(15), 3574 (2022).","journal-title":"Cancers"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00708-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T13:24:22Z","timestamp":1757165062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00708-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: An internal SPSS data file was mistakenly included as Supplementary Information and made publicly available. This file contained sensitive or unpublished raw data that was not intended for public sharing. Therefore, the Supplementary Information file and the Acknowledgements section referencing it have been removed.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval for the study was obtained from the Gazi University Ethics Committee on December 13, 2023, with the application number 27b4ab49-d82f-413f-8878-ad4fd24f4115.Ethics committee approval has been obtained stating that informed consent will not be required due to the retrospective nature of the stud.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"15781"}}